

# CITATION REPORT

List of articles citing

**A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men**

**DOI: 10.3389/fphar.2020.609522**

**Frontiers in Pharmacology, 2020, 11, 609522.**

**Source:** <https://exaly.com/paper-pdf/78783047/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
3	Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial.. <i>Expert Review of Clinical Immunology</i> , <b>2022</b> ,	5.1	2
2	Current status and prospects of IL-6 targeting therapy. <i>Expert Review of Clinical Pharmacology</i> , 1-18	3.8	1
1	Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Gerilimumab (GB224), a recombinant humanized interleukin-6 monoclonal antibody, in healthy Chinese adults: A randomized controlled dose escalation study. <b>2023</b> , 32, 161-170		0